Edition:
United States

Teva Pharmaceutical Industries Ltd (TEVA.TA)

TEVA.TA on Tel Aviv Stock Exchange

2,690.00ILa
22 Jul 2019
Change (% chg)

-60.00 (-2.18%)
Prev Close
2,750.00
Open
2,752.00
Day's High
2,796.00
Day's Low
2,684.00
Volume
974,668
Avg. Vol
1,234,793
52-wk High
9,475.00
52-wk Low
2,684.00

Latest Key Developments (Source: Significant Developments)

Teva Announces FDA Approval Of Airduo Digihaler Inhalation Powder
Monday, 15 Jul 2019 08:30am EDT 

July 15 (Reuters) - Teva Pharmaceutical Industries Ltd ::TEVA ANNOUNCES FDA APPROVAL OF AIRDUO® DIGIHALER™ (FLUTICASONE PROPIONATE 113 MCG AND SALMETEROL 14 MCG) INHALATION POWDER.TEVA PHARMACEUTICAL INDUSTRIES LTD - AIRDUO DIGIHALER IS EXPECTED TO BECOME COMMERCIALLY AVAILABLE TO PATIENTS BY PRESCRIPTION IN 2020.  Full Article

Teva Announces Launch Of A Generic Version Of Tracleer® (Bosentan) Tablets In The United States
Wednesday, 19 Jun 2019 01:00pm EDT 

Teva Pharmaceutical Industries Ltd ::TEVA ANNOUNCES LAUNCH OF A GENERIC VERSION OF TRACLEER® (BOSENTAN) TABLETS IN THE UNITED STATES.TEVA PHARMACEUTICAL INDUSTRIES LTD - ANNOUNCED LAUNCH OF A GENERIC VERSION OF TRACLEER(®1) (BOSENTAN) TABLETS, 62.5 MG AND 125 MG, IN U.S..  Full Article

Lannett Begins Marketing Generic Adderall
Thursday, 16 May 2019 06:52am EDT 

May 16 (Reuters) - Lannett Company Inc ::LANNETT BEGINS MARKETING GENERIC ADDERALL.LANNETT COMPANY INC - BEGUN MARKETING A GENERIC VERSION OF ADDERALL, AN IMMEDIATE-RELEASE MIXED SALT OF A SINGLE ENTITY AMPHETAMINE TABLET PRODUCT.  Full Article

Jana Partners LLC Dissolves Sole Share Stake In Adobe
Wednesday, 15 May 2019 08:27am EDT 

May 15 (Reuters) - JANA PARTNERS LLC ::JANA PARTNERS LLC DISSOLVES SOLE SHARE STAKE IN ADOBE INC - SEC FILING.JANA PARTNERS LLC DISSOLVES SOLE SHARE STAKE IN TEVA PHARMACEUTICAL INDUSTRIES' SPONSORED ADRS - SEC FILING.JANA PARTNERS - CHANGE IN HOLDINGS ARE AS OF MARCH 31, 2019 AND COMPARED WITH THE PREVIOUS QUARTER ENDED AS OF DECEMBER 31, 2018.  Full Article

Teva Announces Launch Of A Generic Version Of Tarceva In The United States
Thursday, 9 May 2019 04:06pm EDT 

May 9 (Reuters) - Teva Pharmaceutical Industries Ltd ::TEVA ANNOUNCES LAUNCH OF A GENERIC VERSION OF TARCEVA® (ERLOTINIB) TABLETS IN THE UNITED STATES.TEVA PHARMACEUTICAL INDUSTRIES LTD - LAUNCH OF A GENERIC VERSION OF TARCEVA (ERLOTINIB) TABLETS, 100 AND 150 MG, IN U.S..  Full Article

Teva Pharmaceutical Industries Q1 Non-GAAP Earnings Per Share $0.60
Thursday, 2 May 2019 07:00am EDT 

Teva Pharmaceutical Industries Ltd ::TEVA REPORTS FIRST QUARTER 2019 FINANCIAL RESULTS.Q1 NON-GAAP EARNINGS PER SHARE $0.60.Q1 GAAP LOSS PER SHARE $0.10.Q1 REVENUE $4.3 BILLION.FULL YEAR 2019 REVENUES AND EPS GUIDANCE REAFFIRMED.FULL YEAR 2019 REVENUES AND EPS GUIDANCE REAFFIRMED.ON TRACK TO REDUCE OUR TOTAL COST BASE BY $3 BILLION BY END OF 2019.TEVA PHARMACEUTICAL - SPEND BASE REDUCTION OF $2.5 BILLION SINCE INITIATION OF RESTRUCTURING PLAN IN 2018; ON-TRACK TO ACHIEVE $3.0 BILLION BY END OF 2019.COPAXONE REVENUES IN EUROPE SEGMENT IN Q1 OF 2019 DECREASED BY 26% TO $114 MILLION, COMPARED TO Q1 OF 2018.TEVA PHARMACEUTICAL INDUSTRIES - GENERIC PRODUCTS REVENUES IN NORTH AMERICA SEGMENT IN Q1 DECREASED BY 11% TO $966 MILLION, VERSUS Q1 2018.AS OF MARCH 31, 2019, DEBT WAS $28,624 MILLION, COMPARED TO $28,916 MILLION AS OF DECEMBER 31, 2018.TEVA PHARMACEUTICAL INDUSTRIES - COPAXONE REVENUES IN NORTH AMERICA SEGMENT IN Q1 DECREASED BY 56% TO $208 MILLION, VERSUS Q1 2018.  Full Article

FDA Says Teva Voluntarily Recalling 44 Lots Of Losartan Potassium Tablets
Monday, 29 Apr 2019 06:20pm EDT 

April 29 (Reuters) - Teva Pharmaceutical Industries Ltd ::FDA - ALERTING PATIENTS & HEALTH CARE PROFESSIONALS TO VOLUNTARY RECALL OF 44 LOTS OF LOSARTAN POTASSIUM TABLETS MANUFACTURED BY TEVA PHARMACEUTICALS.FDA - TEVA IS RECALLING LOTS OF LOSARTAN-CONTAINING MEDICATION THAT TESTED POSITIVE FOR NMBA ABOVE 9.82 PARTS PER MILLION.FDA - RECALLED PRODUCTS WERE MADE WITH ACTIVE PHARMACEUTICAL INGREDIENT MANUFACTURED BY HETERO LABS.FDA - LEGACY PHARMACEUTICAL PACKAGING EXPANDED ITS RECALL TO INCLUDE ONE ADDITIONAL LOT OF LOSARTAN TABLETS MADE WITH API MANUFACTURED BY HETERO LABS.  Full Article

EU Medicines Agency Panel Recommendations For April 2019
Friday, 26 Apr 2019 11:13am EDT 

April 26 (Reuters) - EU Medicines Agency::EU MEDICINES AGENCY PANEL RECOMMENDATIONS FOR APRIL 2019.EU MEDICINES AGENCY PANEL RECOMMENDS APPROVAL OF GSK’S TWO-DRUG HIV TREATMENT DOVATO (DOLUTEGRAVIR/LAMIVUDINE).EU MEDICINES AGENCY PANEL RECOMMENDS EXTENSION OF THERAPEUTIC INDICATION FOR ASTRAZENECA'S LYNPARZA.EU MEDICINES AGENCY PANEL RECOMMENDS AGAINST APPROVAL OF SANOFI'S PROSTATE CANCER DRUG CABAZITAXEL.  Full Article

Teva Pharmaceuticals Usa, Inc. Issues Voluntary Nationwide Recall Of Losartan Potassium 25 Mg And 100 Mg Tablets Usp
Thursday, 25 Apr 2019 05:11pm EDT 

April 25 (Reuters) - Teva Pharmaceutical Industries Ltd ::TEVA PHARMACEUTICALS USA, INC. ISSUES VOLUNTARY NATIONWIDE RECALL OF LOSARTAN POTASSIUM 25 MG AND 100 MG TABLETS USP, SOLD EXCLUSIVELY TO GOLDEN STATE MEDICAL SUPPLY.TEVA PHARMACEUTICAL USA - RECALL DUE TO DETECTION OF IMPURITY FOUND IN 6 LOTS OF API MANUFACTURED BY HETERO LABS LIMITED.TEVA PHARMACEUTICAL USA - TO DATE, CO HAS NOT RECEIVED ANY REPORTS OF ADVERSE EVENTS RELATED TO LOTS BEING RECALLED.  Full Article

Teva Pharmaceutical Industries Says CEO's FY 2018 Total Compensation Was $32.5 Mln
Tuesday, 16 Apr 2019 04:47pm EDT 

April 16 (Reuters) - Teva Pharmaceutical Industries Ltd ::TEVA PHARMACEUTICAL INDUSTRIES LTD SAYS CEO KÅRE SCHULTZ'S FY 2018 TOTAL COMPENSATION WAS $32.5 MILLION - SEC FILING.TEVA PHARMACEUTICAL INDUSTRIES LTD SAYS CEO KÅRE SCHULTZ'S FY 2018 TOTAL COMPENSATION INCLUDED BONUS OF $20 MILLION.TEVA PHARMACEUTICAL INDUSTRIES - RATIO OF ANNUAL TOTAL COMPENSATION OF CEO TO THAT OF ANNUAL TOTAL COMPENSATION OF CO'S MEDIAN EMPLOYEE WAS 444 TO 1.  Full Article

Teva loses challenge to Bausch patent on drug Relistor

Canadian pharmaceutical company Bausch Health Companies Inc (formerly Valeant Pharmaceuticals) on Wednesday won a ruling protecting its drug Relistor from U.S. generic competition from Teva Pharmaceuticals Industries Ltd.